Typically, IRA is recommended for individuals with a mild polyposis phenotype—fewer than 20 rectal polyps and fewer than 1000 colonic polyps—which goes along with a genotype where the APC pathogenic variant is outside the mutation cluster region. This evidence concerns the gene APC and colon inflammatory polyp.